St. Louis Financial Planners Asset Management LLC Purchases Shares of 22,399 Abbott Laboratories $ABT

St. Louis Financial Planners Asset Management LLC acquired a new position in Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 22,399 shares of the healthcare product maker’s stock, valued at approximately $2,806,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Cloud Capital Management LLC bought a new position in Abbott Laboratories in the third quarter worth $29,000. Guerra Advisors Inc bought a new stake in Abbott Laboratories in the 3rd quarter valued at $31,000. Delos Wealth Advisors LLC bought a new stake in Abbott Laboratories in the 2nd quarter valued at $32,000. Bridge Generations Wealth Management LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at $33,000. Finally, Copia Wealth Management bought a new position in shares of Abbott Laboratories during the 3rd quarter worth about $38,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $105.58 on Friday. The stock has a market capitalization of $183.88 billion, a price-to-earnings ratio of 28.38, a P/E/G ratio of 1.71 and a beta of 0.74. The firm’s 50-day moving average price is $112.75 and its two-hundred day moving average price is $123.09. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 1-year low of $105.27 and a 1-year high of $139.06.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s payout ratio is currently 67.74%.

Wall Street Analyst Weigh In

ABT has been the topic of a number of analyst reports. Oppenheimer lowered their target price on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Argus lowered their price objective on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Daiwa Securities Group decreased their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Finally, Piper Sandler lowered their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $136.16.

Insider Activity at Abbott Laboratories

In related news, EVP Elizabeth C. Cushman sold 263 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $30,397.54. Following the transaction, the executive vice president owned 38,573 shares in the company, valued at $4,458,267.34. This represents a 0.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the sale, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. The trade was a 1.78% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.